[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.156.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
Less Is More
December 2015

Reconsidering Guidelines on the Use of Pneumococcal Vaccines in Adults 65 Years or Older

Author Affiliations
  • 1Department of Medicine, David Geffen School of Medicine, UCLA (University of California, Los Angeles)
  • 2Department of Medicine, Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2015;175(12):1895-1896. doi:10.1001/jamainternmed.2015.5689

The recent adult pneumococcal vaccine recommendations issued by the Advisory Committee on Immunization Practices (ACIP) and endorsed by the Centers for Disease Control and Prevention are well intentioned but misguided, complex, and not ready for widespread adoption.1

In August 2014, the ACIP1 recommended the newer pneumococcal conjugate vaccine 13 (PCV13) ($152 per dose2) for adults 65 years or older followed 6 to 12 months later by the older pneumococcal polysaccharide vaccine 23 (PPSV23) ($72 per dose2) (Box). The PCV13 covers 12 of 23 pneumococcal serotypes in PPSV23 plus an additional serotype, and contains conjugate protein, which renders a more robust immune response in individuals with immature or impaired immune systems. In the United States, the conjugate vaccine has been recommended for several years for young children and for patients who are immunocompromised.

First Page Preview View Large
First page PDF preview
First page PDF preview
×